

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1.-125. (canceled).

126. (Currently Amended) An isolated polypeptide selected from the group consisting of:

- (a) — a polypeptide comprising an amino acid sequence of SEQ ID NO: 1;
- (b) — a biologically active fragment of the polypeptide of (a); and
- (c) — an immunogenic fragment of the polypeptide of (a).

127. (Currently Amended) An isolated polypeptide of claim 126 consisting of SEQ ID NO: 1 of the polypeptide of (a).

128. (Currently Amended) An isolated polypeptide comprising a fragment of SEQ ID NO: 1, wherein the fragment is selected from the group consisting of: M1-P27, M1-V21, M1-A25, M1-F26, I57-R161, L16-P27, E87-Q131, Q131-R161, S80-R147, Q56-T71, C72-M95, C101-L126, I145-R161, Q56-C72, C78-G100, C101-T122, L144-R161, I57-I115, M1-K55, M1-T117, E108-M163, N107-M163, K110-R161, A28-M163, L22-M163, F26-M163, P27-M163 and combinations thereof, of claim 126 consisting of a biologically active fragment of the polypeptide of (a).

129. (Currently Amended) An isolated polypeptide variant of SEQ ID NO: 1, wherein one or more amino acid differences between SEQ ID NO: 1 and the variant are selected from the group consisting of amino acid positions 1-27, 50, 80, 148, 156, 71, 116, 73 and 123 of SEQ ID NO: 1, of claim 126 consisting of an immunogenic fragment of the polypeptide of (a).

130. (Currently Amended) An isolated polypeptide of claim 126 encoded by a polynucleotide selected from the group consisting of:

- (i) a polynucleotide comprising a ~~polynucleotide sequence of SEQ ID NO: 2;~~
- (ii) ~~a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 2;~~
- (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 2 that specifically uniquely identifies SEQ ID NO: 2; SEQ ID NO: 2.
- (iv) ~~a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i) or (ii) (i), (ii), or (iii);~~
- (v)~~(iii)~~ an RNA equivalent of the polynucleotide of (i), or (ii), (iii) or (iv);
- (vi)~~(iv)~~ a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).

131. (Previously Presented) An isolated polypeptide of claim 126 produced recombinantly.

132. (Currently Amended) An isolated polypeptide of claim 130 produced by culturing a cell transformed with a polynucleotide of (i)-(iv) under conditions suitable for expression of the polypeptide, and recovering the polypeptide so expressed.

133. (Withdrawn) An isolated antibody that specifically binds to a polypeptide of claim 126.

134. (Withdrawn) An isolated antibody of claim 133, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a humanized antibody.

135. (Withdrawn) An isolated antibody of claim 134, wherein said antibody is selected by screening a recombinant immunoglobulin library.

136. (Withdrawn) An isolated antibody of claim 134, wherein said antibody is selected by screening a Fab expression library.

137. (Withdrawn) An isolated antibody that specifically binds to a polypeptide of claim 130.

138. (Withdrawn) An isolated antibody of claim 137, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a humanized antibody.

139. (Withdrawn) An isolated antibody of claim 137, wherein said antibody is selected by screening a recombinant immunoglobulin library.

140. (Withdrawn) An isolated antibody of claim 137, wherein said antibody is selected by screening a Fab expression library.

141. (Withdrawn) A method of detecting a polypeptide of interest in a sample, comprising: incubating the sample with an antibody that specifically binds to a polypeptide of claim 126 under conditions suitable for binding of the antibody to the polypeptide of interest if present in the sample; and

detecting binding of the polypeptide of interest to the antibody, wherein binding indicates the presence or amount of the polypeptide of interest in the sample.

142. (Withdrawn) A method of claim 141, wherein the sample is a body fluid sample from a human.

143. (Withdrawn) An isolated polynucleotide selected from the group consisting of:
- (i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 2;
  - (ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 2;
  - (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 2 that specifically identifies SEQ ID NO: 2.
  - (iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);
  - (v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);
  - (vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).